Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mogoltacin
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- In Vitro (research Context Only)
01
Overview
Mogoltacin is a **sesquiterpene coumarin** compound isolated from the fruits of *Ferula badrakema*. It has been investigated for its potential as an **adjuvant chemotherapeutic agent**. While mogoltacin alone does not exhibit significant cytotoxicity against bladder cancer cell lines (notably transitional cell carcinoma), it can **enhance the cytotoxic effects** of standard chemotherapeutic agents such as vincristine and cisplatin. Mechanistic studies suggest its potentiating effect may involve increasing DNA damage and apoptosis in cancer cells, but it does not significantly affect multidrug resistance transporter activity.
- Other names
- mogoltacin
02
Targets
ABCB1 (P-glycoprotein)
Beyond the preview
Go deeper on mogoltacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mogoltacin.